Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Last trade$114.13
Day change-$0.275 (-0.24%)
Day range$111.99 – $115.85
Volume362,734
Market cap$4.33B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.33B
Price / earnings
81.44×
Price / book
2.66×
Price / sales
3.98×
EV / sales
4.61×
EV / EBITDA
24.82×
Profitability
Earnings per share
$1.40
Return on assets
1.67%
Return on equity
3.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.51×
Current ratio
1.18×
Quick ratio
0.76×
Cash ratio
0.28×
Cash flow
Price / cash flow
26.27×
Price / free cash flow
30.81×
Free cash flow
$140.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NOVT, quarterly periods
Line item
Q3 FY2026 Oct 2, 2026
Q2 FY2026 Jul 3, 2026
Q1 FY2026 Apr 3, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 26, 2025
Q2 FY2025 Jun 27, 2025
Q1 FY2025 Mar 28, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$305.01M
$265.81M
$257.71M
$258.35M
$247.84M
$241.05M
$233.37M
$238.06M
Cost of revenue
$169.37M
$144.89M
$144.13M
$145.09M
$136.92M
$134.3M
$129.01M
$129.84M
Gross profit
$135.64M
$120.92M
$113.58M
$113.26M
$110.92M
$106.75M
$104.35M
$108.23M
Selling, general and administrative
$57.62M
$59.97M
$54.41M
$51.58M
$51.38M
$47.1M
$45.6M
$43.3M
Research and development
$26.35M
$23.97M
$23.25M
$22.87M
$24.09M
$25.29M
$23.24M
$25.29M
Total operating expenses
$121.73M
$102.85M
$86.04M
$88.43M
$89.07M
$91.84M
$71.93M
$81.52M
Operating income
$13.91M
$18.06M
$27.54M
$24.83M
$21.85M
$14.91M
$32.42M
$26.71M
Interest expense
-$8.28M
-$1.11M
$0
$0
-$6.01M
-$5.82M
$0
$0
Income before taxes
$6.35M
$15.9M
$26.35M
$21.68M
$15.76M
$5.79M
$26.42M
$20.8M
Income taxes
$4.33M
$3.36M
$5.26M
$4.21M
$5.11M
$1.29M
$5.21M
$4.33M
Net income
$2.02M
$12.54M
$21.1M
$17.47M
$10.65M
$4.5M
$21.21M
$16.46M
Net income attributable to common shareholders
$2.02M
$12.54M
$21.1M
$17.47M
$10.65M
$4.5M
$21.21M
$16.46M
EBITDA
$64.45M
$45.21M
$44.3M
$47.77M
$44.24M
$43.06M
$43.53M
$47.45M
Basic earnings per share
$0.05
$0.31
$0.52
$0.46
$0.30
$0.12
$0.59
$0.46
Diluted earnings per share
$0.05
$0.30
$0.51
$0.45
$0.30
$0.12
$0.59
$0.46
Recent news
Company coverage with links to the original publishers.
Novanta reported Q3 2026 earnings of $1.05 per share, beating consensus estimates of $0.97, with revenues of $305.01 million exceeding expectations by 1.50%. The company has consistently outperformed estimates over the last four quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The company's industry, Electronics - Miscellaneous Components, ranks in the top 13% of Zacks industries.
Allient (ALNT) reported quarterly earnings of $1.07 per share, beating consensus estimates of $0.74 by 44.6%, with revenues of $164.4 million exceeding expectations by 5.55%. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. Despite outperforming the S&P 500 by 63.8% year-to-date, analysts expect the stock to underperform in the near term.
Zacks highlights the robotics and AI sector as a major growth opportunity, with the general-purpose robotics market projected to grow from under $1 billion in 2025 to $370 billion by 2040. The article examines key industry players including Fanuc, ABB, Keyence, NVIDIA, Intuitive Surgical, and Illumina, and recommends four robotics-focused ETFs (BOTZ, ROBO, ROBT, IBOT) as diversified investment vehicles to capitalize on this trend.
Novanta CEO Matthijs Glastra sold 6,500 shares worth ~$878,458 on Feb. 2, 2026, as part of a pre-established Rule 10b5-1 trading plan adopted in September 2025. The sale is not a warning sign, as the stock has surged 23% year-to-date in 2026 driven by strong business performance and 17% bookings growth. However, with a P/E ratio near 100, the analyst recommends selling rather than buying at current valuations.
American Capital Management increased its Novanta position by 163,005 shares in Q4 2025 for approximately $18.56 million, bringing its total stake to 381,866 shares valued at $45.44 million. While the fund shows confidence in the company, Novanta faces headwinds including meager 1.4% revenue growth and a lofty 99x P/E ratio, though signs of market recovery in medical and industrial OEM sectors offer some optimism.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.